Sep 23, 2026 6 0
Uploaded by mieayamfan
Favorite
Share
More Options
9
Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as treatment for HER2-expressing advanced urothelial cancer in China_Page 1

Open in WPS to view all 9 pages